GT Biopharma, Inc. (GTBP) vs InMed Pharmaceuticals Inc. (INM)
A side-by-side comparison of GT Biopharma, Inc. and InMed Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GTBP
GT Biopharma, Inc.
$6.44HealthcareDelayed quote: Oct 6, 2026, 2:19 PM EDT
INM
InMed Pharmaceuticals Inc.
$1.32HealthcareDelayed quote: Oct 6, 2026, 2:12 PM EDT
Total return — GTBP vs INM
growth of $100 · dividends reinvested · last 10yGTBP -100.0% (-69.0%/yr)INM -99.9% (-52.7%/yr)INM compounded faster over this window
Log scale — wide-divergence pair
GTBP INM
GTBP vs INM: by the numbers
- •GTBP is the larger company ($8M vs $7M market cap).
- •Both run net losses; GTBP's is the smaller (0.00% vs -0.61% net margin).
Metrics side by side
Valuation
| Metric | GTBP | INM |
|---|---|---|
| P/S ratio | N/A | 0.00 |
| P/B ratio | 2.28 | 6.75 |
Profitability
| Metric | GTBP | INM |
|---|---|---|
| Gross margin | 0.00% | 14.92% |
| Operating margin | 0.00% | -0.52% |
| Net margin | 0.00% | -0.61% |
| ROE | -618.74% | -1168.44% |
| ROIC | -457.75% | -995.44% |
Growth (annualized)
| Metric | GTBP | INM |
|---|---|---|
| Total return CAGR (5Y) | -73.13% | -71.98% |
Frequently asked
- How have GTBP and INM total returns compared?
- Over the past 10 years, GTBP delivered -68.76% and INM delivered -52.81% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.